<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393013</url>
  </required_header>
  <id_info>
    <org_study_id>KZR-616-002</org_study_id>
    <nct_id>NCT03393013</nct_id>
  </id_info>
  <brief_title>A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis</brief_title>
  <acronym>MISSION</acronym>
  <official_title>A Phase 1b/2 Study of KZR-616 in Patients With Systemic Lupus Erythematosus With and Without Nephritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kezar Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kezar Life Sciences, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, multi-center study in which patients will receive KZR-616, administered&#xD;
      as a subcutaneous (SC) injection weekly for 13 weeks (Phase 1b) or 24 weeks (Phase 2).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of 2 parts:&#xD;
&#xD;
      Part 1, Phase 1b, is an open-label multiple dose escalation study to evaluate the safety and&#xD;
      tolerability of KZR-616 in patients with systemic lupus erythematosus (SLE) with and without&#xD;
      lupus nephritis. The Phase 1b part of this study fully enrolled October 2020.&#xD;
&#xD;
      Part 2, Phase 2, is an open-label study to evaluate the efficacy and safety of KZR-616 in&#xD;
      patients with active proliferative lupus nephritis (LN) to assess the number of patients with&#xD;
      a 50% reduction in UPCR after 24 weeks of weekly SC injections with KZR-616 when compared to&#xD;
      baseline.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 7, 2018</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1b: To evaluate the safety and tolerability of KZR-616</measure>
    <time_frame>Baseline through 25 weeks</time_frame>
    <description>To evaluate the safety and tolerability of KZR-616 when administered as a SC injection weekly for 13 weeks in adult patients with SLE with and without lupus nephritis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2: To assess the number of patients with lupus nephritis with a 50% reduction in UPCR</measure>
    <time_frame>24 weeks</time_frame>
    <description>To assess the number of patients with lupus nephritis with a 50% reduction in UPCR after 24 weeks of weekly SC injections with KZR-616 when compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: Identify Recommended Phase 2 dose levels (RP2Ds) of KZR-616</measure>
    <time_frame>4 weeks</time_frame>
    <description>Determined through assessment of all AEs and any dose limiting toxicities (DLTs)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1b: To characterize the PK of KZR-616</measure>
    <time_frame>Day 1</time_frame>
    <description>To characterize the pharmacokinetics of KZR-616</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: To evaluate the safety and tolerability of KZR-616 when administered as a SC injection weekly for 24 weeks</measure>
    <time_frame>37 weeks</time_frame>
    <description>Determined through assessment of all AEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 2: To characterize the efficacy of KZR-616 on parameters of renal function when administered as a SC injection weekly for 24 weeks</measure>
    <time_frame>24 weeks</time_frame>
    <description>Determined through assessment of UPCR after 24 weeks when compared to baseline</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Lupus Nephritis</condition>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>KZR-616 60 mg + standard therapy (Phase 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60 mg dose level of KZR-616 selected based on data from the Phase 1 dose escalation and administered to patients with active Lupus Nephritis in combination with standard therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KZR-616 45 mg + standard of care therapy (Phase 1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohort of patients with SLE with and without nephritis to receive 45 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KZR-616 60 mg + standard of care therapy (Phase 1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohort of patients with SLE with and without nephritis to receive 60 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>KZR-616 75 mg + standard of care therapy (Phase 1b)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose escalation cohort of patients with SLE with and without nephritis to receive 75 mg dose level of KZR-616 in combination with standard of care therapy. This arm is fully enrolled and active.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KZR-616</intervention_name>
    <description>Subcutaneous Injection of KZR-616</description>
    <arm_group_label>KZR-616 45 mg + standard of care therapy (Phase 1b)</arm_group_label>
    <arm_group_label>KZR-616 60 mg + standard of care therapy (Phase 1b)</arm_group_label>
    <arm_group_label>KZR-616 60 mg + standard therapy (Phase 2)</arm_group_label>
    <arm_group_label>KZR-616 75 mg + standard of care therapy (Phase 1b)</arm_group_label>
    <other_name>KZR-616 Lyophile</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
        PHASE 1b (fully enrolled):&#xD;
&#xD;
          -  Male or female patients aged 18 to 75 (inclusive)&#xD;
&#xD;
          -  Body Mass Index (BMI) of 18-40 kg/m2&#xD;
&#xD;
          -  Fulfills the 2012 Systemic Lupus International Collaborating Clinics (SLICC)&#xD;
             classification criteria for SLE&#xD;
&#xD;
          -  Have at least one of the following at screening per central lab:&#xD;
&#xD;
               1. Positive antinuclear antibody (ANA) test (1:80 or higher); or&#xD;
&#xD;
               2. Anti-double stranded deoxyribonucleic acid (dsDNA) antibodies elevated to above&#xD;
                  normal (i.e. positive results); or&#xD;
&#xD;
               3. Anti-Smith antibody elevated to above normal (i.e., positive results)&#xD;
&#xD;
          -  Active SLE as indicated by a Systemic Lupus Erythematosus Disease Activity Index 2000&#xD;
             (SLEDAI-2K) total score ≥4 at screening&#xD;
&#xD;
          -  Must have received 1 or more of the following therapies for SLE, each administered at&#xD;
             or higher than the minimum dose indicated for at least 12 weeks (unless discontinued&#xD;
             or dose adjusted for documented drug-related toxicity or size/weight):&#xD;
&#xD;
               1. Hydroxychloroquine 200 mg orally daily in combination with prednisone 10 mg daily&#xD;
                  or equivalent&#xD;
&#xD;
               2. MMF orally 1 g/day or MPA orally 720 mg/day&#xD;
&#xD;
               3. Methotrexate orally or SC 15 mg/wk., or leflunomide orally 10 mg/day&#xD;
&#xD;
               4. Azathioprine (AZA) 100 mg/day or 6-mercaptopurine 50 mg/day (50 or 25 mg/day,&#xD;
                  respectively, permitted in cases of documented thiopurine methyltransferase&#xD;
                  [TPMT] polymorphism) orally&#xD;
&#xD;
               5. Cyclosporine or tacrolimus at doses documented to maintain at least 100 or 5&#xD;
                  ng/mL during the required duration, respectively&#xD;
&#xD;
               6. Cyclophosphamide 500 mg intravenously (IV) every 2 weeks or 500 mg/m2 IV once&#xD;
                  monthly&#xD;
&#xD;
               7. Belimumab 10 mg/kg IV every 2 weeks for 3 doses, followed by 10 mg/kg every 4&#xD;
                  weeks; or 200 mg SC weekly&#xD;
&#xD;
               8. Rituximab 1 g IV (may be given as 500 mg twice)&#xD;
&#xD;
          -  Acceptable screening laboratory values of concern, including:&#xD;
&#xD;
               1. Adequate hematologic criteria&#xD;
&#xD;
               2. Adequate hepatic function&#xD;
&#xD;
               3. eGFR ≥40 mL/min/1.73 m2&#xD;
&#xD;
               4. IgG ≥500 mg/dL&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum beta-human chorionic&#xD;
             gonadotropin (hCG) pregnancy test at screening and a negative urine pregnancy test&#xD;
             prior to the first dose&#xD;
&#xD;
          -  Male patients must use an effective contraception method (e.g. condom with spermicide)&#xD;
             from signing the ICF until their completion of the study&#xD;
&#xD;
        PHASE 2 (enrolling):&#xD;
&#xD;
          -  Male or female patients aged 18 to 75 years (inclusive)&#xD;
&#xD;
          -  BMI of ≥18kg/m2&#xD;
&#xD;
          -  Fulfills the 2012 SLICC classification criteria for SLE&#xD;
&#xD;
          -  At least one of the following at Screening per central lab:&#xD;
&#xD;
               1. Positive ANA test; or&#xD;
&#xD;
               2. Anti-dsDNA antibodies elevated to above normal; or&#xD;
&#xD;
               3. Anti-Smith antibody at Screening elevated to above normal&#xD;
&#xD;
          -  Active lupus nephritis with UPCR ≥1.0 measured in 24-hour urine collection&#xD;
&#xD;
          -  Currently receiving one or more immunosuppressive agents&#xD;
&#xD;
          -  Renal biopsy with a histologic diagnosis of LN (ISN/RPS) Classes III, IV-S or IV-G,&#xD;
             (A) or (A/C) +/- Class V&#xD;
&#xD;
          -  Acceptable screening laboratory values of concern, including:&#xD;
&#xD;
               1. Adequate hematologic criteria&#xD;
&#xD;
               2. Adequate hepatic function&#xD;
&#xD;
               3. eGFR ≥30mL/min/1.73 m2&#xD;
&#xD;
               4. IgG ≥500 mg/dL&#xD;
&#xD;
          -  Female patients of childbearing potential must have a negative serum pregnancy test at&#xD;
             Screening and a negative urine pregnancy test at Baseline&#xD;
&#xD;
          -  Male patients with a partner of childbearing potential must be either congenitally&#xD;
             sterile or surgically sterile (by vasectomy) or willing to use a condom in addition to&#xD;
             having their female partner use another form of contraception&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
        PHASE 1b (fully enrolled):&#xD;
&#xD;
          -  Active central nervous system involvement by autoimmune disease requiring specific&#xD;
             therapeutic intervention within 60 days prior to first day of study treatment.&#xD;
&#xD;
          -  Presence of another rheumatic (overlap) disease that may confound clinical assessments&#xD;
             in the study.&#xD;
&#xD;
          -  History of antiphospholipid syndrome with thromboembolic event within 12 months of&#xD;
             screening or not on an adequate anticoagulation regimen. However, presence of&#xD;
             antiphospholipid antibodies alone (without a history of thromboembolic event) is not&#xD;
             exclusionary.&#xD;
&#xD;
          -  Receipt of any of the following treatments within the following timeframes before&#xD;
             Screening&#xD;
&#xD;
               1. Systemic corticosteroids ≥ 100 mg prednisone or equivalent: 4 weeks&#xD;
&#xD;
               2. Intra-articular therapies, such as corticosteroids or hyaluronic acid&#xD;
                  preparations: 4 weeks&#xD;
&#xD;
               3. Intravenous Immunoglobulin (IVIg): 4 weeks&#xD;
&#xD;
               4. Other non-biologic immunosuppressive agents, such as cyclosporine, tacrolimus: 4&#xD;
                  weeks&#xD;
&#xD;
               5. Cyclophosphamide: 12 weeks&#xD;
&#xD;
               6. Cytokine antagonists, including but not limited to interleukin (IL)-1, IL-6,&#xD;
                  IL-17, IL-12/23, IL-23, interferon (IFN), integrin, and tumor necrosis factor&#xD;
                  (TNF)-α antagonists: 12 weeks&#xD;
&#xD;
               7. B-cell-depleting therapies (e.g., rituximab): 24 weeks with levels of circulating&#xD;
                  cluster of differentiation 19+ (CD19+) B cells within normal limits or 48 weeks&#xD;
                  if CD19+ count is not available&#xD;
&#xD;
               8. Belimumab, abatacept, or atacicept: 12 weeks&#xD;
&#xD;
               9. Other biologics or investigational drugs: 8 weeks or 5 half-lives, whichever is&#xD;
                  longer&#xD;
&#xD;
              10. Transfusion with blood, packed red blood cells, platelets or treatment with&#xD;
                  plasmapheresis or plasma exchange: 6 weeks&#xD;
&#xD;
          -  Patient has had recent serious or ongoing infection, or risk for serious infection&#xD;
&#xD;
               1. Acute or chronic infections:&#xD;
&#xD;
                    -  Requiring systemic antibiotic, antifungal, or antiviral (antimicrobial)&#xD;
                       therapy within 14 days of Week 1, Day 1&#xD;
&#xD;
                    -  Requiring hospitalization or a course of IV antimicrobial therapy within 24&#xD;
                       weeks prior to screening&#xD;
&#xD;
               2. History of severe and/or disseminated viral infections, and/or opportunistic&#xD;
                  infections&#xD;
&#xD;
               3. Known seropositivity for or active infection by human immunodeficiency virus&#xD;
                  (HIV)&#xD;
&#xD;
               4. Active, chronic, or resolved hepatitis B or hepatitis C infection&#xD;
&#xD;
               5. History of progressive multifocal leukoencephalopathy&#xD;
&#xD;
               6. Active or latent tuberculosis (TB), as suggested by chest x-ray within the 12&#xD;
                  weeks prior to screening and/or QuantiFERON®-TB Gold at Screening&#xD;
&#xD;
               7. Receipt of a live-attenuated vaccine within 12 weeks of first day of study&#xD;
                  treatment (Week 1, Day 1)&#xD;
&#xD;
               8. Primary immunodeficiency (unless otherwise considered, in the opinion of the&#xD;
                  investigator and medical monitor, to confer a clinically insignificant infection&#xD;
                  risk, such as deficiency in immunoglobulin A (IgA), C1q, C2, or C4 without a&#xD;
                  history of recurrent infections [3 or more infections in 1 year requiring&#xD;
                  antimicrobial therapy])&#xD;
&#xD;
          -  History of any concurrent illness that has required treatment with oral or parenteral&#xD;
             corticosteroids for more than a total of 2 weeks within the last 24 weeks prior to&#xD;
             signing the ICF&#xD;
&#xD;
          -  Clinical evidence of significant unstable or uncontrolled acute or chronic diseases&#xD;
&#xD;
          -  History of cancer, except for in situ cancer that has been completely excised or has&#xD;
             been curatively treated cancer with no sign of disease for &gt; 5 years&#xD;
&#xD;
          -  Major surgery within 4 weeks before signing the ICF or major surgery planned during&#xD;
             the study period&#xD;
&#xD;
        PHASE 2 (enrolling):&#xD;
&#xD;
          -  Any of the following: dialysis within 12 months prior to screening, rapidly&#xD;
             progressive glomerulonephritis (RPGN), chronic kidney disease not due to lupus&#xD;
             nephritis, &gt;50% sclerosed glomeruli on most recent renal biopsy&#xD;
&#xD;
          -  Presence of another rheumatic (overlap) disease that may confound clinical assessments&#xD;
             in the study. Secondary sicca or Sjogren's syndrome and antiphospholipid antibody&#xD;
             syndrome are allowed&#xD;
&#xD;
          -  History of antiphospholipid syndrome with history of thromboembolic event within 12&#xD;
             months of screening&#xD;
&#xD;
          -  Active central nervous system involvement by autoimmune disease requiring specific&#xD;
             therapeutic intervention within 60 days prior to first day of study treatment.&#xD;
&#xD;
          -  Active or chronic infection&#xD;
&#xD;
          -  Patient has or had any of the following:&#xD;
&#xD;
               1. Progressive multifocal leukoencephalopathy&#xD;
&#xD;
               2. Active or untreated latent TB, per QuantiFERON-TB Gold at Screening&#xD;
&#xD;
               3. Receipt of a live-attenuated vaccine within 12 weeks of Baseline (Week 1, Day 1)&#xD;
&#xD;
               4. Primary immunodeficiency (unless otherwise considered, in the opinion of the&#xD;
                  investigator and medical monitor, to confer a clinically insignificant infection&#xD;
                  risk, such as deficiency in IgA, C1q, C2, or C4 without a history of recurrent&#xD;
                  infections [3 or more infections in 1 year requiring antimicrobial therapy])&#xD;
&#xD;
               5. Primary hematopoietic cell or solid organ transplant&#xD;
&#xD;
          -  Any active or suspected malignancy or history of documented malignancy within the last&#xD;
             5 years before Screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kezar</last_name>
    <role>Study Director</role>
    <affiliation>Kezar Life Sciences, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kezar Life Sciences, Inc.</last_name>
    <phone>(650)822-5600</phone>
    <email>clinicaltrials@kezarbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Academic Medical Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>990022</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Los Angeles Biomedical Research Institute at Harbor</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Florida Nephrology Research, LLC</name>
      <address>
        <city>Coral Springs</city>
        <state>Florida</state>
        <zip>33071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SouthCoast Research Center, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Trials, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Research Maitland</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Downstate Medical Center</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Northwell Health</name>
      <address>
        <city>Great Neck</city>
        <state>New York</state>
        <zip>11021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Feinstein Institute for Medical Research</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NYU Lagone Orthopedic Center - Seligman Center for Advanced Therapeutics</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Akron Nephrology Associates, Inc.</name>
      <address>
        <city>Akron</city>
        <state>Ohio</state>
        <zip>44302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Health Medical Arts Building</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SC Nephrology &amp; Hypertension Center, Inc.</name>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <zip>29118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ramesh C. Gupta, MD</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Sciences Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MedResearch, Inc.</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Management, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobon Uribe</name>
      <address>
        <city>Medellín</city>
        <state>Antioquia</state>
        <zip>50001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologia de Caribe CIRCARIBE S.A.S</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de la Costa</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicity SAS</name>
      <address>
        <city>Santander</city>
        <state>Bucaramanga</state>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Preventive Care Sas</name>
      <address>
        <city>Chía</city>
        <state>Cundinamarca</state>
        <zip>250001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Servimed S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <state>Santander</state>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica de Artritis Temprana</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>076001</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Integral de Reumatologia SA de CV</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44160</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr José Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64020</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cardiología Ignacio Chavez</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Ciencias Médicas y Nutricion &quot;Salvador Zubiran&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>14080</zip>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion en Medicina Interna y Enfermedades Criticas</name>
      <address>
        <city>Cayma</city>
        <state>Arequipa</state>
        <zip>4000</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación Clínica Trujillo E.I.R.L</name>
      <address>
        <city>Trujillo</city>
        <state>La Libertad</state>
        <zip>13011</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigaciones Clinicas SAC</name>
      <address>
        <city>Lima</city>
        <zip>15023</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Delgado</name>
      <address>
        <city>Lima</city>
        <zip>15074</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Unidad de Investigacion en Reumatologia e Inmunologia Clinica San Juan Bautista</name>
      <address>
        <city>Lima</city>
        <zip>15431</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medyczne Centrum</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolska</state>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Appletreeclinic Network</name>
      <address>
        <city>Łódź</city>
        <zip>90-349</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bioclinica</name>
      <address>
        <city>Łódź</city>
        <zip>90-368</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kuzbass Clinical Hospital</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Revma-Med</name>
      <address>
        <city>Kemerovo</city>
        <zip>650070</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Omsk</city>
        <zip>644111</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical University</name>
      <address>
        <city>Rostov-on-Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Saratov</city>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tolyatti City Clinical Hospital #1</name>
      <address>
        <city>Togliatti</city>
        <zip>445009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Harmoniya Krasy</name>
      <address>
        <city>Kyiv</city>
        <state>Kyiv Governorate</state>
        <zip>01135</zip>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.kezarlifesciences.com/</url>
    <description>Kezar Life Sciences, Inc. corporate website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 21, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>immunoproteasome inhibition</keyword>
  <keyword>selective proteasome inhibition</keyword>
  <keyword>proteasome</keyword>
  <keyword>lupus nephritis</keyword>
  <keyword>lupus</keyword>
  <keyword>nephritis</keyword>
  <keyword>active proliferative lupus nephritis</keyword>
  <keyword>open-label</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <keyword>lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nephritis</mesh_term>
    <mesh_term>Lupus Nephritis</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

